Single-agent gefitinib with concurrent radiotherapy for locally advanced non-small cell lung cancer harboring mutations of the epidermal growth factor receptor

Isamu Okamoto, Toshiaki Takahashi, Hiroaki Okamoto, Kazuhiko Nakagawa, Koshiro Watanabe, Kiyoshi Nakamatsu, Yasumasa Nishimura, Masahiro Fukuoka, Nobuyuki Yamamoto

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

Introduction: A feasibility study was performed to examine the safety and toxicity profile of daily gefitinib (250. mg) administration with concurrent definitive thoracic radiation therapy (TRT) in patients with unresectable non-small cell lung cancer (NSCLC) of stage III. Methods: Patients received a 14-day induction therapy with gefitinib at 250. mg daily. TRT was initiated on day 15 in 2-Gy fractions administered five times weekly to a total dose of 60. Gy. The primary end point of the study was the rate of treatment completion. Mutation status of the epidermal growth factor receptor gene (EGFR) was evaluated for patients with available tumor specimens. Results: Nine eligible patients enrolled in the study received induction gefitinib monotherapy. Two patients were unable to begin TRT because of the development of progressive disease during the first 2 weeks of the protocol. Three of the remaining seven patients treated with gefitinib and concurrent TRT were unable to complete the planned treatment (two because of pulmonary toxicity and one because of progressive disease), and the study was therefore closed according to the protocol definition. Tumor samples were available for eight patients. EGFR mutations (deletion in exon 19) were detected in two patients, both of whom achieved a partial response and exhibited an overall survival of >5 years. Conclusions: Our results do not support further trials of gefitinib and TRT for unselected NSCLC patients. This therapeutic strategy may hold promise, however, for locally advanced NSCLC in patients with sensitizing EGFR mutations.

Original languageEnglish
Pages (from-to)199-204
Number of pages6
JournalLung Cancer
Volume72
Issue number2
DOIs
Publication statusPublished - May 1 2011
Externally publishedYes

Fingerprint

Epidermal Growth Factor Receptor
Non-Small Cell Lung Carcinoma
Radiotherapy
Mutation
erbB-1 Genes
Thorax
gefitinib
Gene Deletion
Feasibility Studies
Therapeutics
Exons
Neoplasms
Safety
Lung
Survival

All Science Journal Classification (ASJC) codes

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research

Cite this

Single-agent gefitinib with concurrent radiotherapy for locally advanced non-small cell lung cancer harboring mutations of the epidermal growth factor receptor. / Okamoto, Isamu; Takahashi, Toshiaki; Okamoto, Hiroaki; Nakagawa, Kazuhiko; Watanabe, Koshiro; Nakamatsu, Kiyoshi; Nishimura, Yasumasa; Fukuoka, Masahiro; Yamamoto, Nobuyuki.

In: Lung Cancer, Vol. 72, No. 2, 01.05.2011, p. 199-204.

Research output: Contribution to journalArticle

Okamoto, Isamu ; Takahashi, Toshiaki ; Okamoto, Hiroaki ; Nakagawa, Kazuhiko ; Watanabe, Koshiro ; Nakamatsu, Kiyoshi ; Nishimura, Yasumasa ; Fukuoka, Masahiro ; Yamamoto, Nobuyuki. / Single-agent gefitinib with concurrent radiotherapy for locally advanced non-small cell lung cancer harboring mutations of the epidermal growth factor receptor. In: Lung Cancer. 2011 ; Vol. 72, No. 2. pp. 199-204.
@article{4e9d32da2ce442a5b606a0c1b0dbabb6,
title = "Single-agent gefitinib with concurrent radiotherapy for locally advanced non-small cell lung cancer harboring mutations of the epidermal growth factor receptor",
abstract = "Introduction: A feasibility study was performed to examine the safety and toxicity profile of daily gefitinib (250. mg) administration with concurrent definitive thoracic radiation therapy (TRT) in patients with unresectable non-small cell lung cancer (NSCLC) of stage III. Methods: Patients received a 14-day induction therapy with gefitinib at 250. mg daily. TRT was initiated on day 15 in 2-Gy fractions administered five times weekly to a total dose of 60. Gy. The primary end point of the study was the rate of treatment completion. Mutation status of the epidermal growth factor receptor gene (EGFR) was evaluated for patients with available tumor specimens. Results: Nine eligible patients enrolled in the study received induction gefitinib monotherapy. Two patients were unable to begin TRT because of the development of progressive disease during the first 2 weeks of the protocol. Three of the remaining seven patients treated with gefitinib and concurrent TRT were unable to complete the planned treatment (two because of pulmonary toxicity and one because of progressive disease), and the study was therefore closed according to the protocol definition. Tumor samples were available for eight patients. EGFR mutations (deletion in exon 19) were detected in two patients, both of whom achieved a partial response and exhibited an overall survival of >5 years. Conclusions: Our results do not support further trials of gefitinib and TRT for unselected NSCLC patients. This therapeutic strategy may hold promise, however, for locally advanced NSCLC in patients with sensitizing EGFR mutations.",
author = "Isamu Okamoto and Toshiaki Takahashi and Hiroaki Okamoto and Kazuhiko Nakagawa and Koshiro Watanabe and Kiyoshi Nakamatsu and Yasumasa Nishimura and Masahiro Fukuoka and Nobuyuki Yamamoto",
year = "2011",
month = "5",
day = "1",
doi = "10.1016/j.lungcan.2010.08.016",
language = "English",
volume = "72",
pages = "199--204",
journal = "Lung Cancer",
issn = "0169-5002",
publisher = "Elsevier Ireland Ltd",
number = "2",

}

TY - JOUR

T1 - Single-agent gefitinib with concurrent radiotherapy for locally advanced non-small cell lung cancer harboring mutations of the epidermal growth factor receptor

AU - Okamoto, Isamu

AU - Takahashi, Toshiaki

AU - Okamoto, Hiroaki

AU - Nakagawa, Kazuhiko

AU - Watanabe, Koshiro

AU - Nakamatsu, Kiyoshi

AU - Nishimura, Yasumasa

AU - Fukuoka, Masahiro

AU - Yamamoto, Nobuyuki

PY - 2011/5/1

Y1 - 2011/5/1

N2 - Introduction: A feasibility study was performed to examine the safety and toxicity profile of daily gefitinib (250. mg) administration with concurrent definitive thoracic radiation therapy (TRT) in patients with unresectable non-small cell lung cancer (NSCLC) of stage III. Methods: Patients received a 14-day induction therapy with gefitinib at 250. mg daily. TRT was initiated on day 15 in 2-Gy fractions administered five times weekly to a total dose of 60. Gy. The primary end point of the study was the rate of treatment completion. Mutation status of the epidermal growth factor receptor gene (EGFR) was evaluated for patients with available tumor specimens. Results: Nine eligible patients enrolled in the study received induction gefitinib monotherapy. Two patients were unable to begin TRT because of the development of progressive disease during the first 2 weeks of the protocol. Three of the remaining seven patients treated with gefitinib and concurrent TRT were unable to complete the planned treatment (two because of pulmonary toxicity and one because of progressive disease), and the study was therefore closed according to the protocol definition. Tumor samples were available for eight patients. EGFR mutations (deletion in exon 19) were detected in two patients, both of whom achieved a partial response and exhibited an overall survival of >5 years. Conclusions: Our results do not support further trials of gefitinib and TRT for unselected NSCLC patients. This therapeutic strategy may hold promise, however, for locally advanced NSCLC in patients with sensitizing EGFR mutations.

AB - Introduction: A feasibility study was performed to examine the safety and toxicity profile of daily gefitinib (250. mg) administration with concurrent definitive thoracic radiation therapy (TRT) in patients with unresectable non-small cell lung cancer (NSCLC) of stage III. Methods: Patients received a 14-day induction therapy with gefitinib at 250. mg daily. TRT was initiated on day 15 in 2-Gy fractions administered five times weekly to a total dose of 60. Gy. The primary end point of the study was the rate of treatment completion. Mutation status of the epidermal growth factor receptor gene (EGFR) was evaluated for patients with available tumor specimens. Results: Nine eligible patients enrolled in the study received induction gefitinib monotherapy. Two patients were unable to begin TRT because of the development of progressive disease during the first 2 weeks of the protocol. Three of the remaining seven patients treated with gefitinib and concurrent TRT were unable to complete the planned treatment (two because of pulmonary toxicity and one because of progressive disease), and the study was therefore closed according to the protocol definition. Tumor samples were available for eight patients. EGFR mutations (deletion in exon 19) were detected in two patients, both of whom achieved a partial response and exhibited an overall survival of >5 years. Conclusions: Our results do not support further trials of gefitinib and TRT for unselected NSCLC patients. This therapeutic strategy may hold promise, however, for locally advanced NSCLC in patients with sensitizing EGFR mutations.

UR - http://www.scopus.com/inward/record.url?scp=79953777978&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79953777978&partnerID=8YFLogxK

U2 - 10.1016/j.lungcan.2010.08.016

DO - 10.1016/j.lungcan.2010.08.016

M3 - Article

C2 - 20828860

AN - SCOPUS:79953777978

VL - 72

SP - 199

EP - 204

JO - Lung Cancer

JF - Lung Cancer

SN - 0169-5002

IS - 2

ER -